Biotechnology company AcuCort AB (Spotlight:ACUC) announced on Thursday that its drug Zeqmelit is now a registered trademark in the USA.
This trademark protection is pivotal for AcuCort's commercialization efforts in its most significant market. Issued by the United States Patent and Trademark Office, the registration is valid for 10 years and renewable thereafter.
Zeqmelit is also a registered trademark across all EU member states, Norway, the United Kingdom, Switzerland, Australia, India, Israel, China and Japan.
CEO Jonas Jönmark highlights the importance of this milestone for the drug's US commercialization phase.
AcuCort anticipates launching Zeqmelit in the Nordic countries starting 1 September 2024.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member